Multiple patent disclosures pointed to new small-molecule chemistry for both central nervous system and oncology targets. Vivozon reported new heterocyclic dual 5-HT2A/dopamine D2 receptor antagonists aimed at schizophrenia, while Sanofi disclosed new ERK5 (MAPK7) inhibitors for cancer. Separately, other filings underscored ongoing competitive interest in protein degradation and pathway control, including new degrader and binder strategies across oncology. While patents don’t establish clinical efficacy, these updates map where medicinal chemistry budgets are being placed ahead of preclinical-to-clinical transitions.